Frans M.J. Debruyne,
Ronald M. Bukowski,
J. Edson Pontes,
Pieter H.M. de Mulder
e.a.
Springer Berlin Heidelberg
e druk, 1991
9783540528357
Immunotherapy of Renal Cell Carcinoma
Clinical and Experimental Developments
Specificaties
Paperback, 141 blz.
|
Engels
Springer Berlin Heidelberg |
1991
ISBN13: 9783540528357
Rubricering
Levertijd ongeveer 9 werkdagen
Gratis verzonden
Samenvatting
Advanced renal cell carcinoma is refractory to nearly forms
of systemic therapy. For this reason the last decade has
seen numerous research groups working on immunotherapeutic s
trategies against it. Immunotherapy of Renal Cell Carcinoma
reports the contributions of most of the world's leading re-
search groups to two international conferences on the immu-
nobiology of this illness. Sixteen chapters divided in expe-
rimental and clinical studies provide an overview of immuno-
therapy in renal cell carcinoma and a discussion of new la-
boratory approaches to this topic.
Specificaties
ISBN13:9783540528357
Taal:Engels
Bindwijze:paperback
Aantal pagina's:141
Uitgever:Springer Berlin Heidelberg
Inhoudsopgave
Experimental Data.- Considerations in Immunotherapy of Genitourinary Neoplasia.- Murine Renal Cancer (Renca) Model: Background and Preclinical Studies.- Renal Cell Carcinoma: Experimental Metastases.- Oncogenes in Renal Cell Carcinoma.- Molecular Basis and Clinical Relevance of MDR1 Gene Expression in Renal Cell Carcinoma.- Radioimmunoconjugates in Renal Cell Carcinoma.- Interferon and Tumor Necrosis Factor in Renal Cell Carcinoma Model Systems.- Clinical Experience with Biological Response Modifiers in Renal Cell Carcinoma.- Rationale for Immunotherapy in Renal Cell Carcinoma.- Treatment of Renal Cell Carcinoma with Interferon.- Combination Therapy with Interferon in Renal Cell Carcinoma.- Recombinant Interferon Alpha Plus Vinblastine in Metastatic Renal Cell Cancer: Updated Results.- Monotherapy and Combination Therapy with Interferon-?, Interferon-?, and Tumor Necrosis Factor-? in Metastatic Renal Cell Carcinoma.- Treatment of Advanced Renal Cell Carcinoma by Systemic Low-Dose Recombinant Interleukin-2.- Direct Lymphatic Immunotherapy for Metastatic Renal Cell Carcinoma.- Combination Therapy of Renal Cell Carcinoma with Interleukin-2 and Interferon Alpha: The Cleveland Clinic Experience.- Tumor Infiltrating Lymphocytes in Human Renal Cell Carcinoma: Adoptive Immunotherapy and Characterization of Interleukin-2 Expanded Tumor-Infiltrating Lymphocytes.- Active Specific Immunotherapy in Renal Cell Carcinoma: Optimization.